Journal
CLINICAL EPIDEMIOLOGY
Volume 14, Issue -, Pages 83-93Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CLEP.S341048
Keywords
glucocorticoids; steroid; VTE; asthma
Categories
Ask authors/readers for more resources
This study evaluated the risk of VTE associated with the use of glucocorticoids in patients with asthma. The results showed that current and systemic glucocorticoid use was associated with a dose-response increased risk of incident VTE.
Background: Glucocorticoids, the class of steroids used in management of asthma, have been observed to be associated with adverse events such as increased coagulation and inhibition of fibrinolysis. This study evaluated the risk of VTE in relation to the use of glucocorticoids in patients with asthma. Methods: We conducted a nested case-control study among patients aged 20-59 years with asthma who received at least one glucocorticoid prescription during 1995-2015 in the UK based Clinical Practice Research Datalink GOLD. We used descriptive analyses and conditional logistic regression to evaluate the risk of VTE associated with glucocorticoid use. Results: The adjusted ORs (aORs) (95% CI) for VTE in patients exposed to glucocorticoids were 1.9 (1.6-2.3), 1.4 (1.1-1.8), and 1.2 (0.9-1.5) for current, recent, and past glucocorticoid users, respectively, compared to the unexposed. The aORs (95% CI) for VTE in patients exposed to systemic glucocorticoid and inhaled glucocorticoids, compared to the unexposed, were 3.5 (2.7-4.5) and 1.5 (1.3-1.8), respectively. Conclusion: Current and systemic glucocorticoid use was associated with a dose-response increased risk of incident idiopathic VTE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available